Komori
Governance197ATAUNS Laboratories,Inc.Pharmaceuticals

Notice Regarding the Transition to a Company with an Audit and Supervisory Committee and Changes in Directors and Executive Officers

Subject to approval at the general meeting of shareholders, the company will transition from a company with a board of corporate auditors to a company with an Audit and Supervisory Committee. In connection with the transition, 3 outside directors who are Audit and Supervisory Committee members will be appointed, while 2 directors and 2 corporate auditors are expected to retire.

Worth reading
70In focus
Scored from 2 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

Planned transition to a company with an Audit and Supervisory Committee (currently a company with a board of corporate auditors)
Number of directors5 director candidates after the transition (including 3 outside directors)
Committee2
Audit and Supervisory Committee3 outside members / total number of members is 非開示
Changes this time

Planned transition from a company with a board of corporate auditors to a company with an Audit and Supervisory Committee. 3 outside directors who are Audit and Supervisory Committee members are expected to be appointed, while 2 directors and 2 corporate auditors are expected to retire.

Governance structure
ItemDetails
Corporate Governance StructurePlanned transition to a company with an Audit and Supervisory Committee (currently a company with a board of corporate auditors)
Number of directors5 director candidates after the transition (including 3 outside directors)
CommitteeAudit and Supervisory Committee, 3 outside members / total number of members is Not disclosed
Changes this timePlanned transition from a company with a board of corporate auditors to a company with an Audit and Supervisory Committee. 3 outside directors who are Audit and Supervisory Committee members are expected to be appointed, while 2 directors and 2 corporate auditors are expected to retire.
Items this document does not state (4)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

By making Audit and Supervisory Committee members part of the Board of Directors, the company will strengthen the Board's auditing and supervisory functions, accelerate decision-making, and further enhance corporate governance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Transition to a Company with an Audit and Supervisory Committee and Changes in Directors and Executive Officers | TAUNS Laboratories,Inc. (197A) timely disclosure | Komori